Skip to main content
Equibles
BCTX logo

BCTX · BriaCell Therapeutics Corp.

Track BCTX — free

Use BCTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BCTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.77 -0.01 (-0.13%)
Going-concern doubt — flagged Jun 9, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.”
View the 10-Q filed Jun 9, 2026
Market Cap
$33.15M
Shares
8.70M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.77 Open$3.61 Day$3.55–4.10 52W close$2.74–13.79 Avg vol 30d414K Short int399K · 4.6% float · 3.3d Short vol46% Last earningsOct 28, 2022 DataAug 2025–Aug 2026 Filing10-Q · Jun 9

Raw chart and full-history price indicators begin at the captured split on Aug 25, 2025; bars on opposite sides are not compared.

Up next

FQ1-27 quarter ends
~Oct 31, 2026 Est
Latest filing: 10-Q
filed Jun 9, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.57
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg +9%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 9%
near low
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +9%
trailing
6-month return −7%
trailing
YTD return −47%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.59% of float · ▼ -2.3% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Squeeze score 78
high risk · 0–100
Fundamentals
Weak
EPS growth −42%
Y/Y
Free cash flow $-28.6M
Balance sheet $10.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 115%
annualized · 1-yr
Max drawdown −80%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
+9% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
9% Bearish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.59% of float · ▼ -2.3% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 9% Range high $14
vs 200-day avg -25% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCTX
BriaCell Therapeutics Corp.
this stock
$33.15M -47.0% — — 4.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +21.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.30B +8.0% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $63.81B +21.2% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
46.4%
Net QoQ
-1.3M sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
398.9K
Days to cover
3.3d
Change
-9.4K sh
View
Short Volume
Short vol %
46%
As of
Aug 25, 2026
Short Total
View
Fails to Deliver
FTD shares
446
Value
$1.6K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
57.3%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-26.3M
EPS diluted
$-62.19
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 26, 2026
This year
9
View
Exempt Offerings
Offering
$27.2M
Filed
Jun 15, 2021
View
Earnings & Events
Earnings Calls
Last call
Oct 28, 2022
View

Performance

Raw-price comparisons begin at the captured split on Aug 25, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BCTX +6.8% +8.7% -7.4% +9.6% -47.0%
SPY -0.2% +3.4% +11.8% +2.5% +12.3%
vs SPY +7.0% +5.3% -19.2% +7.1% -59.3%
Key facts CIK 1610820 CUSIP 107930307 13F (30d) 26 filings 26 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)